middle.news
Imugene’s Azer-Cel CAR T Therapy Delivers 75% Response Rate in Tough Lymphoma Cases
10:05am on Thursday 31st of July, 2025 AEST
•
Healthcare
Read Story
Imugene’s Azer-Cel CAR T Therapy Delivers 75% Response Rate in Tough Lymphoma Cases
10:05am on Thursday 31st of July, 2025 AEST
Key Points
Azer-cel Phase 1b trial achieves 75% overall response rate with 6 complete responses
First dose level cleared in intravenous arm of onCARlytics Phase 1 trial
First Australian patient dosed in PD1-Vaxx Phase II Neo-POLEM trial
US patents granted for onCARlytics and PD1-Vaxx with extended protection
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Imugene (ASX:IMU)
OPEN ARTICLE